Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

994211

registered interest
date	24/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans the National Institute for Health and Care Excellence has to facilitate commercial discussions between manufacturers and NHS England at an early stage in its evaluations of highly specialised technologies.
tabling member constituency	Sheffield, Hallam
tabling member printed	Jared O'Mara
uin	183457
answer	answer is ministerial correction date of answer 01/11/2018 answer text <p>The National Institute for Health and Care Excellence (NICE) it has recently set up a commercial function that specifically focuses on engaging in discussions around commercial arrangements - The Commercial and Managed Access Programme. Through this function, NICE will provide companies with opportunities to engage in commercial and managed access conversations with both NICE and NHS England.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 01/11/2018 16:46:48 answering member 4067 label Biography information for Steve Brine
tabling member	4661 label Biography information for Jared O'Mara

992642

registered interest
date	22/10/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the effectiveness of the (a) criteria used for and (b) long term data collection requirement of the highly specialised technologies process.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	182202
answer	answer is ministerial correction date of answer 30/10/2018 answer text <p>To date, the National Institute for Health and Care Excellence (NICE) has recommended all eight medicines that it has evaluated through its highly specialised technologies (HST) programme for some or all of the eligible patient population, in most cases subject to managed access agreements that specify clinical criteria and data collection requirements. National Health Service organisations are legally required to fund medicines recommended in NICE’s HST guidance, and patients with the rare diseases concerned are now benefitting from access to the medicines in line with NICE’s recommendations.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 182200 question first answered 30/10/2018 15:52:26 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

964649

registered interest
date	03/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what progress his Department has made on establishing an Accelerated Access Collaborative to manage the new accelerated access pathway.
tabling member constituency	Stafford
tabling member printed	Jeremy Lefroy
uin	169360
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The Accelerated Access Collaborative (AAC) has been successfully established, meeting for the first time in January 2018 and agreeing terms of reference and ways of working. Lord Darzi is the new chair of the AAC, replacing Sir Andrew Witty, who stood down to avoid any conflict of interest with his new role as CEO of Optum. We expect that the Accelerated Access Pathway will launch at the next meeting of the AAC, which will be in the autumn.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 14:37:19 answering member 4067 label Biography information for Steve Brine
tabling member	4109 label Biography information for Jeremy Lefroy

964650

registered interest
date	03/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when the accelerated access pathway is planned to begin designating breakthrough products.
tabling member constituency	Stafford
tabling member printed	Jeremy Lefroy
uin	169361
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The Accelerated Access Collaborative will meet this autumn to launch the Accelerated Access Pathway and the first group of products will be part of their discussions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 11/09/2018 14:35:39 answering member 4067 label Biography information for Steve Brine
tabling member	4109 label Biography information for Jeremy Lefroy

964651

registered interest
date	03/09/2018
answering body	Department for Business, Energy and Industrial Strategy
answering dept id	201
answering dept short name	Business, Energy and Industrial Strategy
answering dept sort name	Business, Energy and Industrial Strategy
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Business, Energy and Industrial Strategy, what involvement his Department has had in the establishment of the new accelerated access pathway.
tabling member constituency	Stafford
tabling member printed	Jeremy Lefroy
uin	169362
answer	answer is ministerial correction date of answer 11/09/2018 answer text <p>The establishment of the pathway has been led by the Accelerated Access Collaborative (AAC), working with industry and patients. The establishment of the AAC has been supported by the Office for Life Sciences, which is a joint unit between both the Department for Business, Energy and Industrial Strategy (BEIS) and the Department of Health and Social Care (DHSC). A member of the BEIS departmental board sits on the AAC.</p> answering member constituency East Surrey answering member printed Mr Sam Gyimah question first answered 11/09/2018 14:24:44 answering member 3980 label Biography information for Mr Sam Gyimah
tabling member	4109 label Biography information for Jeremy Lefroy

937431

registered interest
date	09/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what his policy priorities are in the Accelerated Access Pathway programme; and what the implications are of that programme for life-extending treatments.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	162145
answer	answer is ministerial correction date of answer 17/07/2018 answer text <p>In December 2017, the Government published the Life Sciences Sector Deal, which detailed our commitments to taking forward the ambition in the Life Sciences Industrial Strategy. This included implementing the response to the Accelerated Access Review, which sets out a plan to increase the rate of uptake of innovative products.</p><p> </p><p>In delivering this response, the Government has brought together the key Government, National Health Service and industry partners to form the Accelerated Access Collaborative (AAC) which will drive the uptake and adoption of innovation in the NHS, identifying and supporting the innovations that will be most transformative for patients.</p><p> </p><p>The AAC will oversee the Accelerated Access Pathway, streamlining regulatory and market access decisions, and providing additional support to increase uptake of the most transformative innovations.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 17/07/2018 11:34:46 answering member 4067 label Biography information for Steve Brine
tabling member	4658 label Biography information for Alex Sobel

917333

registered interest
date	05/06/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether the products for the accelerated access pathway have now been selected; and when an announcement on such products is planned.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	150123
answer	answer is ministerial correction date of answer 13/06/2018 answer text <p>We are currently in the process of appointing a new chair for the Accelerated Access Collaborative (AAC). Following this appointment, the AAC will meet to launch the Accelerated Access Pathway and will consider the first group of products as part of their discussions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 13/06/2018 15:22:22 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

906390

registered interest
date	17/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the announcement of the treatments selected for the accelerated access pathway.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	145338
answer	answer is ministerial correction date of answer 23/05/2018 answer text <p>The Accelerated Access Collaborative will meet shortly to launch the Accelerated Access Pathway, and will consider the first group of products as part of their discussions.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 23/05/2018 15:32:51 answering member 4067 label Biography information for Steve Brine
tabling member	4131 label Biography information for Jim Shannon

904023

registered interest
date	14/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to shorten the approval process time for treatments that are not selected for the accelerated access pathway.
tabling member constituency	Leeds North West
tabling member printed	Alex Sobel
uin	143872
answer	answer is ministerial correction date of answer 22/05/2018 answer text <p>The Life Sciences Industrial Strategy set out our vision of being a world-leader in developing and bringing to market innovative medicines to improve patient outcomes. It highlighted the importance of evolving and simplifying the access system for new medicines by implementing, and building on, the findings of the Accelerated Access Review.</p><p> </p><p>The response to the Accelerated Access Review, published last year, set out a series of actions the Government and the National Health Service are taking to increase the rate of uptake of innovative products. We have brought together the key Government, NHS and industry partners together through the newly formed Accelerated Access Collaborative, who will oversee the Accelerated Access Pathway, to streamline regulatory and market access decisions, getting breakthrough products that we believe will be truly transformative to patients more quickly. The response also committed to £86 million of support, including £39 million to improve local adoption and uptake of innovative medical technologies through a greater role for the Academic Health and Science Networks and £6 million to help the NHS to adopt and integrate new technologies into everyday practice, through the Pathway Transformation Fund. These build on our existing schemes to encourage quicker patient access such as the Early Access to Medicines Scheme and the Innovation Technology Tariff. Additionally, the Innovation Scorecard tracks the uptake of cost-effective new medicines approved by the National Institute for Health and Care Excellence.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 22/05/2018 14:12:45 answering member 4067 label Biography information for Steve Brine
tabling member	4658 label Biography information for Alex Sobel

900158

registered interest
date	08/05/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Medical Treatments: Innovation
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions he has had with NHS England on ensuring equitable access to treatments following a positive scientific opinion through the Early Access to Medicines Scheme.
tabling member constituency	St Ives
tabling member printed	Derek Thomas
uin	141865
answer	answer is ministerial correction date of answer 16/05/2018 answer text <p>The Life Sciences Industrial Strategy set out our vision of being a world-leader in developing and bringing to market innovative medicines to improve patient outcomes. It highlighted the importance of evolving and simplifying the access system for new medicines by implementing, and building on, the findings of the Accelerated Access Review. The Early Access to Medicines Scheme (EAMS) is an important part of delivering on this ambition.</p><p> </p><p>The Department works closely with NHS England to make a success of EAMS, jointly attending a task group with industry, the devolved administrations and arms length bodies to drive improvements to the scheme. NHS England is involved throughout the EAMS process, receiving advance notice before a product receives a positive Scientific Opinion. This enables NHS England to carry out earlier engagement with industry to prepare to provide access to the drug during the EAMS period.</p><p> </p><p>Access to drugs through EAMS will not be universal, however as it is for individual clinicians to determine whether they believe it is right to offer the medicine to patients. We believe this is the right approach because EAMS products are unlicensed medicines. For a drug that applies to specialised commissioning, access will only be allowed in those centres who meet the appropriate service specification.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 16/05/2018 11:32:30 answering member 4067 label Biography information for Steve Brine
tabling member	4532 label Biography information for Derek Thomas